CVOT trials completed after 2008 showed that new glucose lowering agents like the DPP-4 inhibitors saxagliptin, alogliptin, and sitagliptin and the GLP-1 receptor agonist lixisenatide are safe with respect to CV outcomes in high CV risk patient populations with long T2D duration (for more details on patient selection, see Table 2) under standard care for both CVD and diabetes. Here, GLP1R is linked to diabetes mellitus.